Novo Nordisk Insider Sale, CFO Handover and Australian Wegovy Approval Cap a Busy Week
Published on 11/11/2026 at 09:01 | Editorial boerse-global.de
Novo Nordisk disclosed a fresh batch of share buybacks on Monday, alongside an insider transaction from its research chief and a leadership change in its finance department — corporate housekeeping that unfolded in the same week the Danish drugmaker won Australian approval for its Wegovy tablet and lifted its full-year outlook.
Buyback tally reaches DKK 11.8 billion
Since the programme began on 4 February, the company had repurchased roughly 42.6 million B shares by Friday, at a total cost of about DKK 11.8 billion. Monday's announcement covered purchases made between 3 and 6 November, including 890,000 B shares bought for DKK 243.6 million — all executed inside the existing framework.
Research head offloads 12,000 shares
Martin Holst Lange, the board member responsible for research and development and the company's scientific chief, sold 12,000 shares on 4 November. The disposal, disclosed in a company notice, fetched DKK 3,420,000.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
La Corte to take over finance as Knudsen departs
Also on 4 November, Novo Nordisk named Luigi La Corte as its next chief financial officer, according to Reuters. La Corte was CFO of Galderma at the time of the appointment. Karsten Munk Knudsen will leave the group at year-end to pursue other professional opportunities.
Guidance range narrowed upward
The prior week brought a more upbeat forecast. At constant exchange rates, Novo Nordisk now expects both revenue and operating profit to land anywhere between a 2% decline and 2% growth in 2026. The previous band had stretched from a 6% drop to flat.
Q3 revenue of DKK 79.2 billion
Third-quarter 2026 net revenue came in at DKK 79.2 billion, up 4% at constant currencies, while adjusted operating profit reached DKK 31.7 billion. The Wegovy tablet contributed DKK 5.39 billion in sales. By the end of the quarter the pill had been launched in the US, the United Arab Emirates, the UK and Germany, with rollouts in four more countries following.
Australia's Therapeutic Goods Administration cleared the Wegovy tablets in four strengths on 3 November, covering weight management and a reduction in cardiovascular risk for eligible adults. Novo Nordisk expected the product to be available before the end of the year.
Ad
Novo Nordisk Stock: New Analysis - 11 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
